

Paul Emery

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5951088/paul-emery-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

648 papers	67,971 citations	117 h-index	251 g-index
742 ext. papers	78,805 ext. citations	6.2 avg, IF	7.45 L-index

#	Paper	IF	Citations
648	Prioritising referrals of individuals at-risk of RA: guidance based on results of a 10-year national primary care observational study.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 26	5.7	0
647	COVID-19 vaccine-induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1.. <i>Lancet Rheumatology, The</i> , 2022 ,	14.2	1
646	Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 47	5.7	2
645	RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients.. <i>Scientific Data</i> , 2022 , 9, 196	8.2	0
644	Perturbations of the gut microbiome in anti-CCP positive individuals at risk of developing rheumatoid arthritis. <i>Rheumatology</i> , 2021 , 60, 3380-3387	3.9	2
643	A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis.. <i>Frontiers in Immunology</i> , 2021 , 12, 803175	8.4	1
642	Perceptions and experiences of individuals at-risk of rheumatoid arthritis (RA) knowing about their risk of developing RA and being offered preventive treatment: systematic review and thematic synthesis of qualitative studies. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	2
641	Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021 ,	5.9	1
640	Ultrasound shows swollen joints are the better proxy for synovitis than tender joints in DMARD-naïve early psoriatic arthritis.. <i>Rheumatology Advances in Practice</i> , 2021 , 5, rkab086	1.1	0
639	Current issues in rheumatoid arthritis-associated interstitial lung disease. <i>Lancet Rheumatology, The</i> , 2021 , 3, e798-e807	14.2	4
638	In anti-CCP+ at-risk individuals, radiographic bone erosions are uncommon and are not associated with the development of clinical arthritis. <i>Rheumatology</i> , 2021 , 60, 3156-3164	3.9	2
637	Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway. <i>Rheumatology</i> , 2021 , 60, 4048-4054	3.9	7
636	COVID-19 vaccination and antirheumatic therapy. <i>Rheumatology</i> , 2021 , 60, 3496-3502	3.9	39
635	The PREdictor of MALnutrition in Systemic Sclerosis (PREMASS) Score: A Combined Index to Predict 12 Months Onset of Malnutrition in Systemic Sclerosis. <i>Frontiers in Medicine</i> , 2021 , 8, 651748	4.9	1
634	Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study. <i>Rheumatology</i> , 2021 , 60, 5194-5204	3.9	6
633	Clinical, Radiologic, and Functional Outcomes Following Methotrexate Withdrawal in Etanercept-Treated Patients with Active Early Rheumatoid Arthritis: A Subanalysis of COMET Year 2 by Week 52 DAS28 Status. <i>Open Rheumatology Journal</i> , 2021 , 15, 31-38	0.2	
632	Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	4

631	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 71-87	2.4	50
630	Dysbiosis in the oral microbiomes of anti-CCP positive individuals at risk of developing rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 162-168	2.4	21
629	Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission. <i>Arthritis and Rheumatology</i> , 2021 , 73, 759-768	9.5	12
628	Differential Binding of Sarilumab and Tocilizumab to IL-6R α and Effects of Receptor Occupancy on Clinical Parameters. <i>Journal of Clinical Pharmacology</i> , 2021 , 61, 714-724	2.9	10
627	How should we treat palindromic rheumatism? A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 266-277	5.3	6
626	Muscle deterioration due to rheumatoid arthritis: assessment by quantitative MRI and strength testing. <i>Rheumatology</i> , 2021 , 60, 1216-1225	3.9	3
625	TNF- α Regulates Human Plasmacytoid Dendritic Cells by Suppressing IFN- α Production and Enhancing T Cell Activation. <i>Journal of Immunology</i> , 2021 , 206, 785-796	5.3	10
624	Interferon-related gene expression in response to TNF inhibitor treatment in ankylosing spondylitis patients: a pilot study. <i>Rheumatology</i> , 2021 , 60, 3607-3616	3.9	2
623	Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. <i>MAbs</i> , 2021 , 13, 1868078	6.6	6
622	Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1800-1809	9.5	2
621	EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1286-1298	2.4	6
620	A core set of risk factors in individuals at risk of rheumatoid arthritis: a systematic literature review informing the EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. <i>RMD Open</i> , 2021 , 7,	5.9	4
619	Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review. <i>Arthritis Research and Therapy</i> , 2021 , 23, 3	5.7	5
618	Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis. <i>Rheumatology</i> , 2021 , 60, 3679-3688	3.9	3
617	Anti-carbamylated protein antibodies: are they useful for the diagnosis of rheumatoid arthritis?. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 146-150	2.2	
616	Receptor activator of nuclear factor kappa-B ligand (RANKL) serum levels are associated with progression to seropositive/negative rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 456-462	2.2	1
615	Interleukin-7: a potential factor supporting B-cell maturation in the rheumatoid arthritis synovium. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 253-262	2.2	
614	Anti-carbamylated protein antibodies: are they useful for the diagnosis of rheumatoid arthritis?. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 146-150	2.2	2

613	Ultrasound erosions in the feet best predict progression to inflammatory arthritis in anti-CCP positive at-risk individuals without clinical synovitis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 901-907 ^{2.4}	13
612	Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020 , 22, 115	5.7 5
611	Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. <i>Lancet Rheumatology, The</i> , 2020 , 2, e437-e445	14.2 460
610	How Are Rheumatologists Managing Anticyclic Citrullinated Peptide Antibodies-positive Patients Who Do Not Have Arthritis?. <i>Journal of Rheumatology</i> , 2020 , 47, 305-306	4.1 7
609	Third-Generation Anti-Cyclic Citrullinated Peptide Antibodies Improve Prediction of Clinical Arthritis in Individuals at Risk of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1820-1828	9.5 7
608	Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. <i>RMD Open</i> , 2020 , 6,	5.9 1
607	Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 464-471	2.4 10
606	Reply. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1231-1233	9.5
605	Identification of a Human Polymorphism That Predicts Rheumatoid Arthritis Severity. <i>Frontiers in Immunology</i> , 2020 , 11, 1336	8.4 2
604	T-cell subset abnormalities predict progression along the Inflammatory Arthritis disease continuum: implications for management. <i>Scientific Reports</i> , 2020 , 10, 3669	4.9 5
603	Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasis. <i>Rheumatology</i> , 2020 , 59, 2838-2846	3.9 5
602	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 685-699 ^{2.4}	8.51
601	Defining remission in rheumatoid arthritis: does it matter to the patient? A comparison of multi-dimensional remission criteria and patient reported outcomes. <i>Rheumatology</i> , 2020 , 59, 613-621	3.9 10
600	Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1023-1030 ^{2.4}	6
599	Comparing Psoriatic Arthritis Low-field Magnetic Resonance Imaging, Ultrasound, and Clinical Outcomes: Data from the TICOPA Trial. <i>Journal of Rheumatology</i> , 2020 , 47, 1338-1343	4.1 5
598	Prevention and cure: The major unmet needs in the management of rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2020 , 110, 102399	15.5 10
597	A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 123-131	2.4 116
596	Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data. <i>Rheumatology and Therapy</i> , 2020 , 7, 121-131	4.4 8

595	B Cell Tetherin: A Flow Cytometric Cell-Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020 , 72, 769-779	9.5	8
594	The Role of the Microbiome in Driving RA-Related Autoimmunity. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 538130	5.7	4
593	Pulmonary intravascular coagulopathy in COVID-19 pneumonia - AuthorsPreply. <i>Lancet Rheumatology, The</i> , 2020 , 2, e460-e461	14.2	12
592	Lessons for rituximab therapy in patients with rheumatoid arthritis. <i>Lancet Rheumatology, The</i> , 2020 , 2, e497-e509	14.2	8
591	It's never too soon to treat rheumatoid arthritis: finally, some supportive evidence. <i>Lancet Rheumatology, The</i> , 2020 , 2, e311-e313	14.2	0
590	The Role of Ultrasound Across the Inflammatory Arthritis Continuum: Focus on "At-Risk" Individuals. <i>Frontiers in Medicine</i> , 2020 , 7, 587827	4.9	3
589	Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity. <i>Nature Communications</i> , 2020 , 11, 6149	17.4	23
588	Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open-Label Extension of a Randomized Clinical Trial. <i>ACR Open Rheumatology</i> , 2020 , 2, 672-680	3.5	5
587	Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020 , 22, 188	5.7	2
586	Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab. <i>Frontiers in Medicine</i> , 2020 , 7, 498	4.9	7
585	Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1414-1422	2.4	14
584	Response to: Ultrasound findings in palindromic rheumatism by Sanmarti. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e31	2.4	2
583	Response to: Interosseous tendon inflammation of rheumatoid arthritis: what's the real meaning? by Deng. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e84	2.4	
582	Clinical trial and Real-world data support switching from a bio-originator to its biosimilar. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e44	2.4	3
581	Longterm Drug Survival of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2020 , 47, 493-501	4.1	9
580	Evolving treatment paradigms for rheumatoid arthritis: Translating comprehensive patient evaluations into personalized therapy. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1549	5.3	
579	Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis. <i>Arthritis Care and Research</i> , 2020 , 72, 959-964	4.7	3
578	Muscle stiffness in rheumatoid arthritis is not altered or associated with muscle weakness: A shear wave elastography study. <i>Modern Rheumatology</i> , 2020 , 30, 617-625	3.3	1

577	Long-term follow-up of patients in the Tight Control of inflammation in early Psoriatic Arthritis (TICOPA) trial. <i>Rheumatology</i> , 2020 , 59, 807-810	3.9	4
576	Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. <i>Lancet Rheumatology</i> , 2019 , 1, e85-e94	14.2	38
575	MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019 , 46, 887-895	4.1	6
574	Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1812-1823	9.5	40
573	Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	25
572	Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial. <i>Rheumatology and Therapy</i> , 2019 , 6, 409-419	4.4	5
571	Prevalence of Periodontal Disease and Periodontopathic Bacteria in Anti-Cyclic Citrullinated Protein Antibody-Positive At-Risk Adults Without Arthritis. <i>JAMA Network Open</i> , 2019 , 2, e195394	10.4	47
570	Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis. <i>RMD Open</i> , 2019 , 5, e000898	5.9	8
569	Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients. <i>Rheumatology</i> , 2019 , 58, 2162-2169	3.9	17
568	Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. <i>Lancet</i> , 2019 , 393, 2303-2311	40	143
567	Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren's syndrome. <i>RMD Open</i> , 2019 , 5, e000885	5.9	9
566	Quantifying circulating Th17 cells by qPCR: potential as diagnostic biomarker for rheumatoid arthritis. <i>Rheumatology</i> , 2019 , 58, 2015-2024	3.9	3
565	089 Single centre cohort of refractory rheumatoid arthritis also identifies a rare subgroup of multiple targeted therapy class non-response. <i>Rheumatology</i> , 2019 , 58,	3.9	1
564	Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study. <i>RMD Open</i> , 2019 , 5, e000840	5.9	4
563	Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis. <i>Rheumatology</i> , 2019 , 58, 1684-1686	3.9	3
562	A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1437-1449	9.5	46
561	Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. <i>Rheumatology</i> , 2019 ,	3.9	21
560	MRI inflammation of the hand interosseous tendons occurs in anti-CCP-positive at-risk individuals and may precede the development of clinical synovitis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 781-786	2.4	9

559	First cardiovascular MRI study in individuals at risk of rheumatoid arthritis detects abnormal aortic stiffness suggesting an anti-citrullinated peptide antibody-mediated role for accelerated atherosclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1138-1140	2.4	5
558	Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2019 , 58, 849-858	3.9	49
557	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1553-1570	9.5	31
556	Reduction in stiffness of proximal leg muscles during the first 6 months of glucocorticoid therapy for giant cell arteritis: A pilot study using shear wave elastography. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22, 1891-1899	2.3	2
555	Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. <i>Trials</i> , 2019 , 20, 429	2.8	39
554	Normal values and test-retest variability of stimulated-echo diffusion tensor imaging and fat fraction measurements in the muscle. <i>British Journal of Radiology</i> , 2019 , 92, 20190143	3.4	8
553	IL-6 Mediated Transcriptional Programming of Naïve CD4+ T Cells in Early Rheumatoid Arthritis Drives Dysregulated Effector Function. <i>Frontiers in Immunology</i> , 2019 , 10, 1535	8.4	8
552	The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019 , 21, 164	5.7	12
551	Determining MRI Inflammation Targets When Considering a Rheumatoid Arthritis Treat-to-Target Strategy: Results of a Randomized, Placebo-Controlled Trial. <i>Advances in Therapy</i> , 2019 , 36, 2384-2393	4.1	3
550	Palindromic rheumatism as part of the rheumatoid arthritis continuum. <i>Nature Reviews Rheumatology</i> , 2019 , 15, 687-695	8.1	21
549	Genetic associations with radiological damage in rheumatoid arthritis: Meta-analysis of seven genome-wide association studies of 2,775 cases. <i>PLoS ONE</i> , 2019 , 14, e0223246	3.7	8
548	Imaging in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and osteoarthritis: An international viewpoint on the current knowledge and future research priorities. <i>European Journal of Rheumatology</i> , 2019 , 6, 38-47	1.7	7
547	Muscle shear wave elastography in idiopathic inflammatory myopathies: a case-control study with MRI correlation. <i>Skeletal Radiology</i> , 2019 , 48, 1209-1219	2.7	28
546	The effect of ageing on shear wave elastography muscle stiffness in adults. <i>Aging Clinical and Experimental Research</i> , 2019 , 31, 1755-1763	4.8	47
545	THU0072 ULTRASOUND PREDICTS IMMINENT PROGRESSION TO ARTHRITIS IN ANTI-CCP POSITIVE AT-RISK INDIVIDUALS 2019 ,		2
544	What Should Be the Primary Target of "Treat to Target" in Psoriatic Arthritis?. <i>Journal of Rheumatology</i> , 2019 , 46, 38-42	4.1	16
543	Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. <i>Rheumatology</i> , 2019 , 58, 859-868	3.9	72
542	Safety evaluation of adalimumab in immune-mediated inflammatory disorders: a rheumatological point of view. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 11-19	4.1	0

541	Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study. <i>Arthritis and Rheumatology</i> , 2019 , 71, 626-631	9.5	36
540	Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus. <i>Rheumatology</i> , 2019 ,	3.9	7
539	Identification of a distinct imaging phenotype may improve the management of palindromic rheumatism. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 43-50	2.4	17
538	Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus. <i>Rheumatology</i> , 2019 , 58, 304-312	3.9	14
537	Response to: Can ultrasound of the major salivary glands assess histopathological changes induced by treatment with rituximab in primary Sjögren's syndrome?. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e28	2.4	2
536	European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis. <i>Rheumatology</i> , 2019 , 58, 254-259	3.9	7
535	Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 988-995	2.4	31
534	Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Impact of residual Inflammation Detected via Imaging Techniques, rug Levels and Patient Characteristics on the Outcome of Dose Tapering of Adalimumab in clinical Remission Rheumatoid Arthritis (RA) patients (PREDICTRA). <i>BMJ Open</i> , 2018 , 8, e019667	3	6
533	Extension Study of PF-05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2018 , 70, 1598-1606	4.7	18
532	Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study. <i>RMD Open</i> , 2018 , 4, e000564	5.9	23
531	Transforming Growth Factor β Activation Primes Canonical Wnt Signaling Through Down-Regulation of Axin-2. <i>Arthritis and Rheumatology</i> , 2018 , 70, 932-942	9.5	14
530	Rheumatoid arthritis. <i>Nature Reviews Disease Primers</i> , 2018 , 4, 18001	51.1	750
529	Scleroderma fibroblasts suppress angiogenesis via TGF- β /caveolin-1 dependent secretion of pigment epithelium-derived factor. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 431-440	2.4	14
528	Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 412-416	2.4	53
527	Diagnostic test accuracy of ultrasound for synovitis in rheumatoid arthritis: systematic review and meta-analysis. <i>Rheumatology</i> , 2018 , 57, 49-58	3.9	30
526	Effect of Fatigue, Older Age, Higher Body Mass Index, and Female Sex on Disability in Early Rheumatoid Arthritis in the Treatment-to-Target Era. <i>Arthritis Care and Research</i> , 2018 , 70, 361-368	4.7	9
525	Cost-Effectiveness of Tight Control of Inflammation in Early Psoriatic Arthritis: Economic Analysis of a Multicenter Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2018 , 70, 462-468	4.7	11
524	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 3-17	2.4	320

523	Remission in psoriatic arthritis-where are we now?. <i>Rheumatology</i> , 2018 , 57, 1321-1331	3.9	8
522	The effect of unit, depth, and probe load on the reliability of muscle shear wave elastography: Variables affecting reliability of SWE. <i>Journal of Clinical Ultrasound</i> , 2018 , 46, 108-115	1	44
521	Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 165-174	2.4	120
520	Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1432-1439	2.4	48
519	Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1923-1932	9.5	20
518	Comorbidities in Anti-Cyclic Citrullinated Peptide Positive At-Risk Individuals Do Not Differ from Those Patients with Early Inflammatory Arthritis. <i>Frontiers in Medicine</i> , 2018 , 5, 35	4.9	1
517	Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review. <i>Advances in Therapy</i> , 2018 , 35, 1535-1563	4.1	40
516	Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK. <i>Pharmacoeconomics</i> , 2018 , 36, 1015-1027	4.4	10
515	Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. <i>Health Technology Assessment</i> , 2018 , 22, 1-280	4.4	7
514	Predictors of Remission Maintenance after Etanercept Tapering or Withdrawal in Early Rheumatoid Arthritis: Results from the PRIZE Study. <i>Open Rheumatology Journal</i> , 2018 , 12, 179-188	0.2	
513	Defining and characterizing sustained remission in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018 , 37, 885-893	3.9	2
512	The RA-MAP Consortium: a working model for academia-industry collaboration. <i>Nature Reviews Rheumatology</i> , 2018 , 14, 53-60	8.1	12
511	Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 289-292	2.4	18
510	Recent advances in ankylosing spondylitis: understanding the disease and management. <i>F1000Research</i> , 2018 , 7,	3.6	34
509	e48 Effects of baricitinib on haematological laboratory parameters in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2018 , 57,	3.9	3
508	On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis. <i>Rheumatology International</i> , 2018 , 38, 2225-2231	3.6	3
507	Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. <i>RMD Open</i> , 2018 , 4, e000662	5.9	14
506	Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. <i>Pharmacogenomics Journal</i> , 2018 , 18, 528-538	3.5	25

505	Serum IL-7 as diagnostic biomarker for rheumatoid arthritis, validation with EULAR 2010 classification criteria. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 115-120	2.2	11
504	A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 51-57	2.4	157
503	Physical activity but not sedentary activity is reduced in primary Sjögren's syndrome. <i>Rheumatology International</i> , 2017 , 37, 623-631	3.6	10
502	Identifying arthralgia suspicious for progression to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, e14	2.4	2
501	Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1070-1077	3.4	161
500	2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 948-959	2.4	243
499	Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1440-1450	9.5	122
498	Imminent rheumatoid arthritis can be identified in primary care. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, e42	2.4	1
497	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 960-974	7.4	1649
496	Relationship of patient-reported outcomes with MRI measures in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 486-490	2.4	34
495	Ultrasound-detectable grey scale synovitis predicts future fulfilment of the 2010 ACR/EULAR RA classification criteria in patients with new-onset undifferentiated arthritis. <i>RMD Open</i> , 2017 , 3, e000394	5.9	16
494	Development and Validation of the OMERACT Rheumatoid Arthritis Magnetic Resonance Tenosynovitis Scoring System in a Multireader Exercise. <i>Journal of Rheumatology</i> , 2017 , 44, 1688-1693	4.1	20
493	Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre. <i>Rheumatology</i> , 2017 , 56, 1348-1357	3.9	97
492	Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. <i>Lancet, The</i> , 2017 , 390, 457-468	4.0	227
491	Early Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell Transition. <i>Journal of Immunology</i> , 2017 , 198, 4618-4628	5.3	26
490	Obesity and rates of clinical remission and low MRI inflammation in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1743-1746	2.4	24
489	The dynamics of response as measured by multiple composite outcome tools in the Tight Control of inflammation in early Psoriatic Arthritis (TICOPA) trial. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1688-1692	2.4	15
488	Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. <i>RMD Open</i> , 2017 , 3, e000410	5.9	23

487	Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. <i>Rheumatology</i> , 2017 , 56, 1662-1675	3.9	50
486	Modifying the trajectory of asthma-are there lessons from the use of biologics in rheumatology?. <i>Lancet, The</i> , 2017 , 389, 1082-1084	4.0	1
485	Abatacept reduces disease activity and ultrasound power Doppler in ACPA-negative undifferentiated arthritis: a proof-of-concept clinical and imaging study. <i>Rheumatology</i> , 2017 , 56, 58-67	3.9	5
484	Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the Discrepancy. <i>Arthritis Care and Research</i> , 2017 , 69, 1714-1723	4.7	12
483	Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 88-95	2.4	222
482	Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. <i>RMD Open</i> , 2017 , 3, e000445	5.9	4
481	The GOLMePSa study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes. <i>BMC Musculoskeletal Disorders</i> , 2017 , 18, 303	2.8	8
480	The new ACR/EULAR criteria for rheumatoid arthritis can identify patients with same disease activity but less damage by ultrasound. <i>European Journal of Rheumatology</i> , 2017 , 4, 118-121	1.7	7
479	52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis. <i>Rheumatology</i> , 2017 , 56, 2093-2101	3.9	40
478	Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review. <i>Rheumatology International</i> , 2017 , 37, 1789-1798	3.6	15
477	Periodontal disease and periodontal bacteria as triggers for rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017 , 31, 19-30	5.3	61
476	Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. <i>Annals of the Rheumatic Diseases</i> , 2017 ,	2.4	67
475	The OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging (MRI) Scoring System: Updated Recommendations by the OMERACT MRI in Arthritis Working Group. <i>Journal of Rheumatology</i> , 2017 , 44, 1706-1712	4.1	66
474	What can palindromic rheumatism tell us?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017 , 31, 90-98	5.3	17
473	Autoimmune-autoinflammatory rheumatoid arthritis overlaps: a rare but potentially important subgroup of diseases. <i>RMD Open</i> , 2017 , 3, e000550	5.9	18
472	Synovial tissue research: a state-of-the-art review. <i>Nature Reviews Rheumatology</i> , 2017 , 13, 463-475	8.1	107
471	Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis: Results from the Yorkshire Early Arthritis Register. <i>Journal of Rheumatology</i> , 2017 , 44, 1331-1340	4.1	3
470	Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1829-1836	2.4	57

469	A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1937-1948	9.5	21
468	An investigation into the variability between different shear wave elastography systems in muscle. <i>Medical Ultrasonography</i> , 2017 , 19, 392-400	1.4	30
467	Development and validation of rheumatoid arthritis magnetic resonance imaging inflammation thresholds associated with lack of damage progression. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 607-613	2.2	7
466	Six-joint ultrasound in rheumatoid arthritis: a feasible approach for implementing ultrasound in remission. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 853-856	2.2	2
465	The initiation of autoimmunity at epithelial surfaces: a focus on rheumatoid arthritis and systemic lupus erythematosus. <i>Discovery Medicine</i> , 2017 , 24, 191-200	2.5	12
464	Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 408-12	2.4	53
463	Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry. <i>Rheumatology</i> , 2016 , 55, 544-52	3.9	7
462	The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review. <i>Rheumatology</i> , 2016 , 55, 485-94	3.9	15
461	MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 170-7	2.4	36
460	Absence of Scleroderma pattern at nail fold capillaroscopy valuable in the exclusion of Scleroderma in unselected patients with Raynaud's Phenomenon. <i>BMC Musculoskeletal Disorders</i> , 2016 , 17, 342	2.8	11
459	Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study. <i>Rheumatology</i> , 2016 , 55, 2181-2190	3.9	18
458	Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate. <i>Rheumatology</i> , 2016 , 55, 1458-65	3.9	11
457	Does high-dose extended course cyclophosphamide and methylprednisolone pulse therapy have a role in the management of systemic sclerosis-related interstitial lung disease?. <i>Rheumatology</i> , 2016 , 55, 2273-2275	3.9	1
456	Confirmation on the immunogenicity assay used in the SB4 phase III study: response to the comments by Meacci et al. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e40	2.4	8
455	Response to: Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required by Moots et al. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e25	2.4	5
454	The prevalence of tenosynovitis of the interosseous tendons of the hand in patients with rheumatoid arthritis. <i>European Radiology</i> , 2016 , 26, 444-50	8	13
453	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 16-22	2.4	156
452	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 3-15	2.4	814

451	Ultrasound findings predict progression to inflammatory arthritis in anti-CCP antibody-positive patients without clinical synovitis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 2060-2067	2.4	70
450	Enriching case selection for imminent RA: the use of anti-CCP antibodies in individuals with new non-specific musculoskeletal symptoms - a cohort study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1452-6	2.4	44
449	Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1114-9	2.4	21
448	Discordance between the predictors of clinical and imaging remission in patients with early rheumatoid arthritis in clinical practice: implications for the use of ultrasound within a treatment-to-target strategy. <i>Rheumatology</i> , 2016 , 55, 1177-87	3.9	27
447	Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials. <i>Arthritis Care and Research</i> , 2016 , 68, 299-307	4.7	6
446	Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 490-8	2.4	86
445	Glucocorticoids and Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2016 , 42, 33-46, vii	2.4	32
444	Halo naevi, vitiligo and diffuse alopecia areata associated with tocilizumab therapy. <i>Oxford Medical Case Reports</i> , 2016 , 2016, omw027	0.6	7
443	Recent Trends of Ultrasound in Rheumatology. <i>Journal of Rheumatic Diseases</i> , 2016 , 23, 11	1.2	
442	A new window of opportunity in rheumatoid arthritis: targeting at-risk individuals. <i>Current Opinion in Rheumatology</i> , 2016 , 28, 260-6	5.3	13
441	Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e65	2.4	8
440	Response to: Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration by Marshall et al. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e38	2.4	6
439	Novel algorithms for the pragmatic use of ultrasound in the management of patients with rheumatoid arthritis: from diagnosis to remission. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1902-1908	2.4	64
438	Musculoskeletal ultrasound in rheumatology in Korea: targeted ultrasound initiative survey. <i>International Journal of Rheumatic Diseases</i> , 2016 , 19, 335-42	2.3	2
437	Response to: Lower anti-drug antibodies with etanercept biosimilar: Can Ctough explain the differences by Shah. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e61	2.4	1
436	Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016 , 18, 294	5.7	22
435	Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1501-5	2.4	17
434	Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines. <i>RMD Open</i> , 2016 , 2, e000282	5.9	46

433	A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA). <i>BMC Musculoskeletal Disorders</i> , 2016 , 17, 61	2.8	8
432	A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies. <i>American Journal of Human Genetics</i> , 2016 , 98, 857-868	11	14
431	A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2867-2877	9.5	122
430	Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1428-37	2.4	166
429	Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial. <i>Arthritis Care and Research</i> , 2016 , 68, 744-52	4.7	28
428	Preclinical Rheumatoid Arthritis: Progress Toward Prevention. <i>Arthritis and Rheumatology</i> , 2016 , 68, 779-88	3.8	57
427	A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 129-38	3.8	39
426	Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 2165-74	2.4	27
425	Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1586-91	9.5	60
424	A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization. <i>Rheumatology International</i> , 2015 , 35, 1837-49	3.6	16
423	Remission in rheumatoid arthritis: is it all the same?. <i>Expert Review of Clinical Pharmacology</i> , 2015 , 8, 575-86	3.8	9
422	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 963-9	2.4	27
421	Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1734-8	3.4	20
420	Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. <i>Lancet, The</i> , 2015 , 386, 2489-98	4.0	271
419	High-resolution MRI assessment of dactylitis in psoriatic arthritis shows flexor tendon pulley and sheath-related enthesitis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 185-9	2.4	76
418	An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1195-201	2.4	34
417	Rheumatoid arthritis in 2014: Exciting times for RA research. <i>Nature Reviews Rheumatology</i> , 2015 , 11, 69-70	8.1	4
416	The specificity of ultrasound-detected bone erosions for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 897-903	2.4	60

415	Whole-body MRI of patients with polymyalgia rheumatica identifies a distinct subset with complete patient-reported response to glucocorticoids. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 2188-92	2.4	47
414	Anti-Porphyromonas gingivalis Antibodies in Rheumatoid Arthritis: Comment on the Article by Seror et al. <i>Arthritis and Rheumatology</i> , 2015 , 67, 3329-30	9.5	2
413	Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. <i>Arthritis Research and Therapy</i> , 2015 , 17, 325	5.7	10
412	The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2591-600	9.5	63
411	The OMERACT MRI in Arthritis Working Group - Update on Status and Future Research Priorities. <i>Journal of Rheumatology</i> , 2015 , 42, 2470-2	4.1	10
410	Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. <i>New England Journal of Medicine</i> , 2015 , 373, 2534-48	59.2	619
409	Etanercept tapering in rheumatoid arthritis. <i>New England Journal of Medicine</i> , 2015 , 372, 489-90	59.2	0
408	Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 19-26	2.4	155
407	A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren's Syndrome. <i>PLoS ONE</i> , 2015 , 10, e0143970	3.7	24
406	B-cell depletion 2015 , 472-478		2
405	Is localized autoimmunity the trigger for rheumatoid arthritis? Unravelling new targets for prevention. <i>Discovery Medicine</i> , 2015 , 20, 129-35	2.5	19
404	Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. <i>Rheumatology</i> , 2014 , 53, 1560-9	3.9	136
403	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 516-28	2.4	224
402	Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with magnetic resonance imaging-detected synovitis and radiographic progression. <i>Arthritis and Rheumatology</i> , 2014 , 66, 794-802	9.5	43
401	Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 349-56	2.4	267
400	Certolizumab pegol in rheumatoid arthritis: current update. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 841-50	5.4	10
399	Sustained remission with etanercept tapering in early rheumatoid arthritis. <i>New England Journal of Medicine</i> , 2014 , 371, 1781-92	59.2	141
398	Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1968-74	2.4	61

397	The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 420-7	2.4	28
396	Why is there persistent disease despite biologic therapy? Importance of early intervention. <i>Arthritis Research and Therapy</i> , 2014 , 16, 115	5.7	8
395	Determining a magnetic resonance imaging inflammatory activity acceptable state without subsequent radiographic progression in rheumatoid arthritis: results from a followup MRI study of 254 patients in clinical remission or low disease activity. <i>Journal of Rheumatology</i> , 2014 , 41, 398-406	4.1	61
394	Reply: To PMID 24757132. <i>Arthritis and Rheumatology</i> , 2014 , 66, 3245-6	9.5	
393	An immunological biomarker to predict MTX response in early RA. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 2047-53	2.4	40
392	Health-related utility values of patients with primary Sjögren's syndrome and its predictors. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1362-8	2.4	63
391	Response to Dr Bredemeier's letter. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, e34	2.4	
390	Response to: Which B-cell subset should we target in lupus? By Ferraccioli and Houssiau. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, e20	2.4	3
389	Biologics in systemic lupus erythematosus: current options and future perspectives. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2014 , 75, 440, 442-7	0.8	7
388	Biologics in rheumatoid arthritis: where are we going?. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2014 , 75, 448-9, 451-6	0.8	3
387	Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 909-12	2.4	30
386	Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2014 , 33, 1239-46	3.9	8
385	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 492-509	2.4	1487
384	Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 62-8	2.4	467
383	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 6-16	2.4	308
382	Emergence of proinflammatory autoreactive T-cell responses in preclinical rheumatoid arthritis. <i>Lancet, The</i> , 2014 , 383, S22	40	2
381	TLR dependent XBP-1 activation induces an autocrine loop in rheumatoid arthritis synoviocytes. <i>Journal of Autoimmunity</i> , 2014 , 50, 59-66	15.5	45
380	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. <i>Lancet, The</i> , 2014 , 383, 321-32	40	196

379	Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a multicentre, open-label, randomised controlled trial. <i>Lancet, The</i> , 2014 , 383, S36	4.0	14
378	Defining populations at risk of rheumatoid arthritis: the first steps to prevention. <i>Nature Reviews Rheumatology</i> , 2014 , 10, 521-30	8.1	18
377	Diurnal variation of gait in patients with rheumatoid arthritis: The DIVIGN study. <i>Clinical Biomechanics</i> , 2014 , 29, 811-4	2.2	5
376	A1.52 TLR-Dependent XBP1 activation induces an autocrine loop in rheumatoid arthritis synovial fibroblasts. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, A22.1-A22	2.4	
375	1.63 IL-7 drives the tissue architecture of the RA synovium providing a niche for B-cells to mature. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, A27.2-A28	2.4	
374	I72. Early Arthritis. <i>Rheumatology</i> , 2014 , 53, i16-i16	3.9	
373	Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial. <i>Journal of Rheumatology</i> , 2014 , 41, 1077-87	4.1	28
372	Modulation of peripheral T-cell function by interleukin-7 in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2014 , 16, 511	5.7	17
371	Update on the OMERACT magnetic resonance imaging task force: research and future directions. <i>Journal of Rheumatology</i> , 2014 , 41, 383-5	4.1	3
370	Autoantibodies to posttranslational modifications in rheumatoid arthritis. <i>Mediators of Inflammation</i> , 2014 , 2014, 492873	4.3	55
369	The microanatomic basis of finger clubbing - a high-resolution magnetic resonance imaging study. <i>Journal of Rheumatology</i> , 2014 , 41, 523-7	4.1	10
368	Role of golimumab for the treatment of rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , 2014 , 9, 245-258	1.5	1
367	Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. <i>Rheumatology</i> , 2014 , 53, 186-94	3.9	44
366	The outcome and cost-effectiveness of nurse-led care in people with rheumatoid arthritis: a multicentre randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1975-82	2.4	65
365	Is the glass half full or half empty? Comment on the article by Götner et Al. <i>Arthritis and Rheumatology</i> , 2014 , 66, 1055-6	9.5	1
364	Greater body mass independently predicts less radiographic progression on X-ray and MRI over 1-2 years. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1923-8	2.4	63
363	Is there subclinical synovitis in early psoriatic arthritis? A clinical comparison with gray-scale and power Doppler ultrasound. <i>Arthritis Care and Research</i> , 2014 , 66, 432-9	4.7	64
362	A1.9 Pilot work towards discovery of novel diagnostic biomarker for rheumatoid arthritis using combinations of chemokine receptor expression on peripheral blood cell-subsets. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, A4.1-A4	2.4	

361	Choosing the right rituximab dose for the right patient: comment on the article by Bredemeier et al. <i>Arthritis Care and Research</i> , 2014 , 66, 1591-3	4.7	1
360	MTHFR functional genetic variation and methotrexate treatment response in rheumatoid arthritis: a meta-analysis. <i>Pharmacogenomics</i> , 2014 , 15, 467-75	2.6	15
359	The SwitchPstudy protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug. <i>BMC Musculoskeletal Disorders</i> , 2014 , 15, 452	2.8	19
358	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1755-60	2.4	10
357	Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 2490-8	27.4	405
356	Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk. <i>Pain Practice</i> , 2014 , 14, 378-95		45
355	Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1202-10	2.4	128
354	Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program. <i>PLoS ONE</i> , 2014 , 9, e87379	3.7	64
353	Skin imaging in systemic sclerosis. <i>European Journal of Rheumatology</i> , 2014 , 1, 111-116	1.7	13
352	Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease-modifying anti-rheumatic drugs. <i>Clinical and Experimental Rheumatology</i> , 2014 , 32, 653-60	2.2	16
351	Magnetic resonance imaging assessment of axial psoriatic arthritis: extent of disease relates to HLA-B27. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2274-8		36
350	The TICOPA protocol (Tight Control of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. <i>BMC Musculoskeletal Disorders</i> , 2013 , 14, 101	2.8	83
349	B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress. <i>Expert Review of Clinical Immunology</i> , 2013 , 9, 761-72	5.1	10
348	Etanercept in the treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 1441-50	15.4	5
347	Targeting interleukin-6 in rheumatoid arthritis. <i>Drugs</i> , 2013 , 73, 341-56	12.1	57
346	Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2013 , 382, 1705-13	40	449
345	Assessment of umbilical cord tissue as a source of mesenchymal stem cell/endothelial cell mixtures for bone regeneration. <i>Regenerative Medicine</i> , 2013 , 8, 569-81	2.5	17
344	Emerging drugs for axial spondyloarthritis including ankylosing spondylitis. <i>Expert Opinion on Emerging Drugs</i> , 2013 , 18, 71-86	3.7	9

343	Virtual skin biopsy by optical coherence tomography: the first quantitative imaging biomarker for scleroderma. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1845-51	2.4	58
342	Evaluation of serum biomarkers associated with radiographic progression in methotrexate-naïve rheumatoid arthritis patients treated with methotrexate or golimumab. <i>Journal of Rheumatology</i> , 2013 , 40, 590-8	4.1	6
341	Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1897-904	2.4	96
340	The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. <i>Arthritis and Rheumatism</i> , 2013 , 65, 88-97		19
339	Is there a place for initial treatment with biological DMARDs in the early phase of RA?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013 , 27, 537-54	5.3	8
338	Creative trial design in RA: optimizing patient outcomes. <i>Nature Reviews Rheumatology</i> , 2013 , 9, 183-94	8.1	12
337	Rituximab biosimilars. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 1049-62	5.4	30
336	Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. <i>Lancet, The</i> , 2013 , 381, 1541-50	4.0	460
335	Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 583-9	2.4	68
334	Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 61-71	2.4	161
333	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 482-92	2.4	87
332	Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1702-12		48
331	Allele-dose association of the C5orf30 rs26232 variant with joint damage in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2555-61		17
330	Progression to rheumatoid arthritis in early inflammatory arthritis is associated with low IL-7 serum levels. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1032-6	2.4	22
329	The link between enthesitis and arthritis in psoriatic arthritis: a switch to a vascular phenotype at insertions may play a role in arthritis development. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 992-5	2.4	60
328	Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1496-502	2.4	242
327	Metaanalysis of the association of smoking and PTPN22 R620W genotype on autoantibody status and radiological erosions in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2013 , 40, 1048-53	4.1	11
326	EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 479-81	2.4	85

325	Golimumab, a human anti-tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study. <i>Arthritis Care and Research</i> , 2013 , 65, 1732-42	4.7	29
324	Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 329-36	2.4	122
323	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72 Suppl 2, ii2-34	2.4	96
322	A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis. <i>Postgraduate Medical Journal</i> , 2013 , 89, 231-40	2	14
321	Dr. Keystone, et al, reply. <i>Journal of Rheumatology</i> , 2013 , 40, 732-3	4.1	
320	Statins do not influence clinical response and B cell depletion after rituximab treatment in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 463-4	2.4	14
319	Value of ultrasound in rheumatologic diseases. <i>Journal of Korean Medical Science</i> , 2013 , 28, 497-507	4.7	10
318	LDL cholesterolemia as a novel risk factor for radiographic progression of rheumatoid arthritis: a single-center prospective study. <i>PLoS ONE</i> , 2013 , 8, e68975	3.7	10
317	Comparison of ultrasonography and magnetic resonance imaging for the assessment of clinically defined knee enthesitis in spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2013 , 31, 933-6	2.2	9
316	Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. <i>Autoimmunity Reviews</i> , 2012 , 11, 357-64	13.6	176
315	Therapy switching, augmentation, and discontinuation in patients with osteoarthritis and chronic low back pain. <i>Pain Practice</i> , 2012 , 12, 457-68	3	22
314	Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis. <i>Human Mutation</i> , 2012 , 33, 741-9	4.7	32
313	Relationship between early bone mineral density changes and long-term function and radiographic progression in rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012 , 64, 66-70	4.7	15
312	Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 2012 , 64, 418-22		118
311	Towards an optimum strategy in rheumatoid arthritis. <i>Lancet, The</i> , 2012 , 379, 1682-4	4.0	4
310	Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. <i>Rheumatology</i> , 2012 , 51, 2204-14	3.9	102
309	The evolution of ultrasound in rheumatology. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012 , 4, 399-411	3.8	18
308	Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 553-6	2.4	113

307	Infliximab treatment increases left ventricular ejection fraction in patients with rheumatoid arthritis: assessment of heart function by echocardiography, endothelin 1, interleukin 6, and NT-pro brain natriuretic peptide. <i>Journal of Rheumatology</i> , 2012 , 39, 701-6	4.1	40
306	The role of tocilizumab in the management of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12, 1277-89	5.4	24
305	A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 319-26	2.4	201
304	After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?. <i>Postgraduate Medical Journal</i> , 2012 , 88, 482-6	2	16
303	Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3150-5		66
302	Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life. <i>Journal of Crohn's and Colitis</i> , 2012 , 6 Suppl 2, S224-34	1.5	58
301	IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). <i>Seminars in Arthritis and Rheumatism</i> , 2012 , 42, 131-9	5.3	62
300	Certolizumab pegol for the treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12, 235-49	5.4	29
299	Transcriptional profile of native CD271+ multipotential stromal cells: evidence for multiple fates, with prominent osteogenic and Wnt pathway signaling activity. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2632-43		94
298	Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. <i>Rheumatology</i> , 2012 , 51 Suppl 5, v22-30	3.9	61
297	Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1316-21	2.4	136
296	Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 2035-43	2.4	56
295	After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 799-803	2.4	76
294	Does achieving clinical response prevent work stoppage or work absence among employed patients with early rheumatoid arthritis?. <i>Rheumatology</i> , 2012 , 51, 270-4	3.9	8
293	Ultrasonographic assessment of nail in psoriatic disease shows a link between onychopathy and distal interphalangeal joint extensor tendon enthesopathy. <i>Dermatology</i> , 2012 , 225, 231-5	4.4	107
292	Concomitant cyclophosphamide and oral immunosuppressants with rituximab for systemic lupus erythematosus. <i>Rheumatology</i> , 2012 , 51, 1131-2	3.9	6
291	Ten-year follow-up of SpA-related oligoarthritis involving the knee: the presence of psoriasis but not HLA-B27 or baseline MRI bone oedema predicts outcome. <i>Rheumatology</i> , 2012 , 51, 1099-106	3.9	5
290	Updated meta-analysis of non-melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, e2	2.4	22

289	Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. <i>Journal of Rheumatology</i> , 2012 , 39, 2238-46	4.1	58
288	EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 638-41	2.4	263
287	Combination etanercept and methotrexate provides better disease control in very early (4 months and . <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 989-92	2.4	63
286	Relationship between area-level socio-economic deprivation and autoantibody status in patients with rheumatoid arthritis: multicentre cross-sectional study. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1640-5	2.4	15
285	Biological therapy for rheumatoid arthritis: where are we now?. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2012 , 73, 12-8	0.8	8
284	Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1973-9	2.4	46
283	Autologous Hematopoietic Stem Cell Transplantation Versus Intravenous Pulse Therapy Cyclophosphamide for Severe or Rapidly Progressive Systemic Sclerosis, the Astis Trial. <i>Blood</i> , 2012 , 120, 964-964	2.2	3
282	FcRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy. <i>PLoS ONE</i> , 2012 , 7, e28918	3.7	42
281	Optical coherence tomography: a new tool to assess nail disease in psoriasis?. <i>Dermatology</i> , 2011 , 222, 311-3	4.4	37
280	Improvements in participation in usual daily activities in patients with rheumatoid arthritis treated with abatacept. <i>Value in Health</i> , 2011 , 14, 361-70	3.3	7
279	MRI for the assessment and monitoring of RA--what can it tell us?. <i>Nature Reviews Rheumatology</i> , 2011 , 7, 185-9	8.1	5
278	American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 404-13	2.4	518
277	New therapies in the management of rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2011 , 23, 245-51	5.3	54
276	NSAIDs inhibit in vitro MSC chondrogenesis but not osteogenesis: implications for mechanism of bone formation inhibition in man. <i>Journal of Cellular and Molecular Medicine</i> , 2011 , 15, 525-34	5.6	54
275	A randomised, controlled study of outcome and cost effectiveness for RA patients attending nurse-led rheumatology clinics: study protocol of an ongoing nationwide multi-centre study. <i>International Journal of Nursing Studies</i> , 2011 , 48, 995-1001	5.8	4
274	Golimumab - a new tool in the armoury against inflammatory arthritis. <i>Annals of Medicine</i> , 2011 , 43, 133-41	4.5	11
273	Foot health needs in people with systemic sclerosis: an audit of foot health care provision. <i>Clinical Rheumatology</i> , 2011 , 30, 1611-5	3.9	13
272	Biomarkers in the management of scleroderma: an update. <i>Current Rheumatology Reports</i> , 2011 , 13, 4-12	4.9	20

271	Quantitative magnetization transfer ultrashort echo time imaging of the Achilles tendon. <i>Magnetic Resonance in Medicine</i> , 2011 , 65, 1372-6	4.4	29
270	Extremity magnetic resonance imaging in rheumatoid arthritis: Updated literature review. <i>Arthritis Care and Research</i> , 2011 , 63, 660-5	4.7	11
269	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011 , 63, 573-86		520
268	Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. <i>Arthritis and Rheumatism</i> , 2011 , 63, 603-8		67
267	The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. <i>Arthritis and Rheumatism</i> , 2011 , 63, 1200-10		90
266	B cell biomarkers of rituximab responses in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3038-47		156
265	Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naïve rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3712-22		71
264	Infliximab: 12 years of experience. <i>Arthritis Research and Therapy</i> , 2011 , 13 Suppl 1, S2	5.7	51
263	Do non-steroidal anti-inflammatory drugs have a significant effect on detection and grading of ultrasound-detected synovitis in patients with rheumatoid arthritis? Results from a randomised study. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1746-51	2.4	27
262	Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1895-904	2.4	274
261	Synovitis and osteitis are very frequent in rheumatoid arthritis clinical remission: results from an MRI study of 294 patients in clinical remission or low disease activity state. <i>Journal of Rheumatology</i> , 2011 , 38, 2039-44	4.1	85
260	Relationship between patient-reported disease severity and other clinical outcomes in osteoarthritis: a European perspective. <i>Journal of Medical Economics</i> , 2011 , 14, 381-9	2.4	12
259	Pocket Reference to Early Rheumatoid Arthritis 2011 ,		2
258	Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. <i>Current Medical Research and Opinion</i> , 2011 , 27, 315-25	2.5	12
257	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 909-20	2.4	308
256	Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. <i>Rheumatology</i> , 2011 , 50, 2223-32	3.9	42
255	Myofibroblast specific gene expression signature in systemic sclerosis, more than TGF- β induced activation. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, A31-A31	2.4	
254	Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 98-103	2.4	48

253	Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 423-7	2.4	91
252	Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 2126-30	2.4	28
251	Update on research and future directions of the OMERACT MRI inflammatory arthritis group. <i>Journal of Rheumatology</i> , 2011 , 38, 2031-3	4.1	14
250	Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1968-74	2.4	46
249	Reduced IL-7 serum titres are associated with progression towards rheumatoid arthritis in less than 6 months inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, A2-A2	2.4	
248	Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 792-8	2.4	144
247	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1999-2002	2.4	59
246	Certolizumab pegol in rheumatoid arthritis: a review of Phase III clinical trials and its role in real-life clinical practice. <i>International Journal of Clinical Rheumatology</i> , 2011 , 6, 517-527	1.5	1
245	Effect of intra-articular corticosteroid injections and inflammation on periarticular and generalised bone loss in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 184-7	2.4	20
244	An ultrasonographic study of metatarsophalangeal joint pain: synovitis, structural pathology and their relationship to symptoms and function. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 2140-3	2.4	16
243	Reporting of long-term extension studies: lack of consistency calls for consensus. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 886-90	2.4	52
242	Cell receptor-ligand interaction, signalling, activation and apoptosis ²¹ . Pregnenolone Sulphate is Similar to Dexamethasone in Suppressing the Unfettered Secretion of Hyaluronan: In Vitro Study on Cultured Synovial Fibroblasts from Patients with Longstanding Rheumatoid Arthritis. <i>Rheumatology</i> , 2011 , 50, 1150-1156	3.9	
241	Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1826-30	2.4	114
240	Care needs to be taken when reviewing malignancy data reported from observational studies: comment on the article by Onel and Onel. <i>Arthritis Care and Research</i> , 2011 , 63, 461-3; author reply 463-4	4.7	
239	Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. <i>Nature</i> , 2010 , 464, 713-20	50.4	639
238	Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. <i>Nature Genetics</i> , 2010 , 42, 508-14	36.3	969
237	Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations. <i>Drug, Healthcare and Patient Safety</i> , 2010 , 2, 101-19	1.6	4
236	The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 495-502	2.4	117

235	Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1926-8	2.4	89
234	Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1054-7	2.4	52
233	The American College of Rheumatology/European League Against Rheumatism Criteria for the classification of rheumatoid arthritis: a game changer. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1575-6	2.4	4
232	PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian population. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 666-70	2.4	57
231	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 638-643	2.4	168
230	No evidence for association of the KLF12 gene with rheumatoid arthritis in a large UK cohort. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1407-8	2.4	4
229	Anti-TNF Therapy in Ankylosing Spondylitis: Insights for the Clinician. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2010 , 2, 37-43	3.8	18
228	Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. <i>Rheumatology</i> , 2010 , 49, 1971-4	3.9	42
227	Aspects of TNF inhibitor therapy in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2010 , 20, 325-330	3.3	18
226	Response of symptoms and synovitis to intra-muscular methylprednisolone in osteoarthritis of the hand: an ultrasonographic study. <i>Rheumatology</i> , 2010 , 49, 1093-100	3.9	46
225	Differential pattern of expression of caveolin-1 and AIF-1 in chronic graft-versus-host disease suggests a specific role in the pathogenesis of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, A24-A25	2.4	
224	Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD therapy. <i>Rheumatology</i> , 2010 , 49, 1894-9	3.9	21
223	Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 510-6	2.4	212
222	Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. <i>Journal of Rheumatology</i> , 2010 , 37, 558-67	4.1	212
221	Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 575-8	2.4	36
220	Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1158-61	2.4	99
219	New biologic for treating rheumatoid arthritis: clinical trial experience with tocilizumab. <i>International Journal of Clinical Rheumatology</i> , 2010 , 5, 17-24	1.5	
218	The evidence for whole-spine MRI in the assessment of axial spondyloarthritis. <i>Rheumatology</i> , 2010 , 49, 426-32	3.9	19

217	Association of CD40 with rheumatoid arthritis confirmed in a large UK case-control study. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 813-6	2.4	49
216	Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. <i>Journal of Rheumatology</i> , 2010 , 37, 322-9	4.1	65
215	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 964-75	2.4	1210
214	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1589-95	2.4	117
213	Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. <i>Journal of Investigative Dermatology</i> , 2010 , 130, 1785-96	4.3	447
212	Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab® Efficacy in MTX iNadequate Response) (SERENE). <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1122-35	2.4	222
211	Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1636-42	2.4	134
210	2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1580-8	2.4	2158
209	Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 631-7	2.4	1300
208	The changing management of inflammatory arthritis. <i>Journal of Clinical Rheumatology</i> , 2010 , 16, 403-7	1.1	
207	Confirmation of association of the REL locus with rheumatoid arthritis susceptibility in the UK population. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1572-3	2.4	23
206	Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. <i>Arthritis and Rheumatism</i> , 2010 , 62, 674-82		92
205	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2582-91		182
204	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2569-81		4825
203	Delay in receiving rheumatology care leads to long-term harm. <i>Arthritis and Rheumatism</i> , 2010 , 62, 3519-21		40
202	Aspects of TNF inhibitor therapy in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2010 , 20, 325-30	3.3	8
201	Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. <i>Human Molecular Genetics</i> , 2009 , 18, 2518-22	5.6	70
200	Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2009 , 36, 1429-41	4.1	81

199	The OMERACT psoriatic arthritis magnetic resonance imaging scoring system (PsAMRIS): definitions of key pathologies, suggested MRI sequences, and preliminary scoring system for PsA Hands. <i>Journal of Rheumatology</i> , 2009 , 36, 1816-24	4.1	138
198	Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. <i>Human Molecular Genetics</i> , 2009 , 18, 2693-9	5.6	77
197	Reducing invasiveness, duration, and cost of magnetic resonance imaging in rheumatoid arthritis by omitting intravenous contrast injection -- Does it change the assessment of inflammatory and destructive joint changes by the OMERACT RAMRIS?. <i>Journal of Rheumatology</i> , 2009 , 36, 1806-10	4.1	82
196	The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. <i>Rheumatology</i> , 2009 , 48, 1283-9	3.9	51
195	Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 946-54		218
194	Re-treatment of rheumatoid arthritis patients who were initial nonresponders to rituximab: comment on the article by Thurlings et al. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1867; author reply 1867-8		2
193	Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: A clinical and imaging comparative study. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1915-22		112
192	Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naïve patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1877-87		334
191	Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population. <i>Arthritis and Rheumatism</i> , 2009 , 60, 2565-76		79
190	Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1592-600		71
189	The role of biomarkers in the management of patients with rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2009 , 11, 371-7	4.9	9
188	Rheumatoid arthritis: what has changed?. <i>Skeletal Radiology</i> , 2009 , 38, 109-12	2.7	9
187	Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. <i>Nature Genetics</i> , 2009 , 41, 1313-8	36.3	272
186	Robotic multiwell planar patch-clamp for native and primary mammalian cells. <i>Nature Protocols</i> , 2009 , 4, 244-55	18.8	84
185	Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. <i>Journal of Rheumatology</i> , 2009 , 36, 736-42	4.1	100
184	Etanercept in the longterm treatment of patients with ankylosing spondylitis. <i>Journal of Rheumatology</i> , 2009 , 36, 1256-64	4.1	43
183	The OMERACT MRI inflammatory arthritis group: advances and future research priorities. <i>Journal of Rheumatology</i> , 2009 , 36, 1803-5	4.1	6
182	MRI predicts response to anti-TNF in ankylosing spondylitis. <i>International Journal of Clinical Rheumatology</i> , 2009 , 4, 123-126	1.5	

181	Comparison of autoinflammation and autoimmunity using TRAPS and rheumatoid arthritis as prototypes of these conditions. <i>International Journal of Clinical Rheumatology</i> , 2009 , 4, 681-695	1.5	1
180	Costimulation blockade in rheumatic diseases: where we are?. <i>Current Opinion in Rheumatology</i> , 2009 , 21, 244-50	5.3	21
179	B cell targets in rheumatoid arthritis 2009 , 1-26		
178	TRPC channel activation by extracellular thioredoxin. <i>Nature</i> , 2008 , 451, 69-72	50.4	228
177	Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. <i>Nature Genetics</i> , 2008 , 40, 1156-9	36.3	125
176	Abatacept in the treatment of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2008 , 10 Suppl 1, S5	5.7	32
175	The development of targeted therapies in rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2008 , 31, 219-27.5	30	
174	Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority study. <i>Clinical Therapeutics</i> , 2008 , 30, 70-83	3.5	35
173	Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. <i>Lancet, The</i> , 2008 , 372, 375-82	40	625
172	Role of oestrogen in the development of joint symptoms?. <i>Lancet Oncology, The</i> , 2008 , 9, 817-8	21.7	12
171	Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. <i>Human Molecular Genetics</i> , 2008 , 17, 2274-9	5.6	121
170	Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. <i>Arthritis and Rheumatism</i> , 2008 , 58, 953-63		137
169	The shared epitope hypothesis in rheumatoid arthritis: evaluation of alternative classification criteria in a large UK Caucasian cohort. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1275-83		35
168	Distinct topography of erosion and new bone formation in achilles tendon enthesitis: implications for understanding the link between inflammation and bone formation in spondylarthritis. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2694-9		90
167	Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2993-9		152
166	Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. <i>Arthritis and Rheumatism</i> , 2008 , 58, 3319-29		458
165	Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008 , 59, 1467-74		139
164	An ultrasonographic study of osteoarthritis of the hand: synovitis and its relationship to structural pathology and symptoms. <i>Arthritis and Rheumatism</i> , 2008 , 59, 1756-63		111

163	IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 1516-23	2.4	798
162	Predicting the development of rheumatoid arthritis in patients with recent-onset undifferentiated arthritis. <i>Future Rheumatology</i> , 2008 , 3, 441-444		
161	Using extremity magnetic resonance imaging to assess and monitor early rheumatoid arthritis: the optimal joint combination to be scanned in clinical practice. <i>Journal of Rheumatology</i> , 2008 , 35, 580-3	4.1	8
160	Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. <i>Arthritis and Rheumatism</i> , 2007 , 56, 323-33		360
159	A randomized controlled trial of early intervention with intraarticular corticosteroids followed by sulfasalazine versus conservative treatment in early oligoarthritis. <i>Arthritis and Rheumatism</i> , 2007 , 57, 154-60		25
158	Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. <i>Arthritis and Rheumatism</i> , 2007 , 57, 448-53		63
157	The validity of the inclusion of "lupus headache" in the Systemic Lupus Erythematosus Disease Activity Index. <i>Arthritis and Rheumatism</i> , 2007 , 56, 2812-3		4
156	Development of psoriasis after B cell depletion with rituximab. <i>Arthritis and Rheumatism</i> , 2007 , 56, 2715-8		201
155	Evidence for a different anatomic basis for joint disease localization in polymyalgia rheumatica in comparison with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 3496-501		39
154	Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 3896-908		270
153	Delay in imaging versus clinical response: a rationale for prolonged treatment with anti-tumor necrosis factor medication in early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007 , 57, 1564-7		56
152	Spondylarthrite ankylosante, positivité de HLA-B27 et utilisation des biothérapies. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2007 , 74, 232-236	0.1	1
151	Rheumatoid arthritis association at 6q23. <i>Nature Genetics</i> , 2007 , 39, 1431-3	36.3	328
150	Ankylosing spondylitis, HLA-B27 positivity and the need for biologic therapies. <i>Joint Bone Spine</i> , 2007 , 74, 140-3	2.9	32
149	Quantifying peri-meniscal synovitis and its relationship to meniscal pathology in osteoarthritis of the knee. <i>European Radiology</i> , 2007 , 17, 119-24	8	15
148	Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. <i>Rheumatology International</i> , 2007 , 27, 793-806	3.6	73
147	The future of imaging in monitoring biologic therapy. <i>Nature Clinical Practice Rheumatology</i> , 2007 , 3, 2-3		
146	Hand bone densitometry: a more sensitive standard for the assessment of early bone damage in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1513-7	2.4	29

145	Response to intramuscular methyl prednisolone in inflammatory hand pain: evidence for a targeted clinical, ultrasonographic and therapeutic approach. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 690-2	2.4	9
144	Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 778-81	2.4	43
143	A modification of the Omeract RA MRI score for erosions for use with an extremity MRI system with reduced field of view. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1669-71	2.4	5
142	New therapies for treatment of rheumatoid arthritis. <i>Lancet, The</i> , 2007 , 370, 1861-74	4.0	706
141	Aspects of early arthritis. Biological therapy in early arthritis--overtreatment or the way to go?. <i>Arthritis Research and Therapy</i> , 2007 , 9, 211	5.7	25
140	Imaging inflamed synovial joints. <i>Methods in Molecular Medicine</i> , 2007 , 135, 3-26		4
139	Outcome measurements in scleroderma: results from a delphi exercise. <i>Journal of Rheumatology</i> , 2007 , 34, 501-9	4.1	38
138	The OMERACT Magnetic Resonance Imaging Inflammatory Arthritis Group - advances and priorities. <i>Journal of Rheumatology</i> , 2007 , 34, 852-3	4.1	8
137	A multireader reliability study comparing conventional high-field magnetic resonance imaging with extremity low-field MRI in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2007 , 34, 854-6	4.1	21
136	A multicenter reliability study of extremity-magnetic resonance imaging in the longitudinal evaluation of rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2007 , 34, 857-8	4.1	13
135	Developing a magnetic resonance imaging scoring system for peripheral psoriatic arthritis. <i>Journal of Rheumatology</i> , 2007 , 34, 859-61	4.1	34
134	Ankylosing spondylitis: new treatment modalities. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006 , 20, 559-70	5.3	9
133	Infliximab treatment maintains employability in patients with early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006 , 54, 716-22		86
132	A high-resolution magnetic resonance imaging study of distal interphalangeal joint arthropathy in psoriatic arthritis and osteoarthritis: are they the same?. <i>Arthritis and Rheumatism</i> , 2006 , 54, 1328-33		142
131	The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. <i>Arthritis and Rheumatism</i> , 2006 , 54, 1390-400		795
130	Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006 , 54, 1410-4		139
129	Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2793-806		1241
128	MR imaging findings in the hands. <i>Radiology</i> , 2006 , 241, 320-1; author reply 321	20.5	1

127	Infliximab for rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2006 , 2, 193-207	5.1	5
126	Nonresponse to tumor necrosis factor antagonists--is there any point in re-treatment?. <i>Nature Clinical Practice Rheumatology</i> , 2006 , 2, 288-9		8
125	Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 2559-70	4	30
124	Use of prognostic markers in early rheumatoid arthritis to identify patients at risk of destructive disease. <i>Expert Review of Clinical Immunology</i> , 2006 , 2, 853-7	5.1	
123	Inhibiting toll-like receptors in inflammatory disease. <i>Lancet, The</i> , 2006 , 368, 821-2	40	5
122	Biomarkers: Strategies to predict outcome of rheumatoid arthritis. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2006 , 3, 11-16		
121	Treatment of rheumatoid arthritis. <i>BMJ, The</i> , 2006 , 332, 152-5	5.9	90
120	Rituximab: B-cell depletion therapy for the treatment of rheumatoid arthritis. <i>Future Rheumatology</i> , 2006 , 1, 293-302		
119	Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. <i>Annals of Internal Medicine</i> , 2006 , 144, 865-76	8	524
118	Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. <i>Arthritis and Rheumatism</i> , 2006 , 54, 702-10		336
117	Abatacept in the treatment of rheumatoid arthritis. <i>Therapeutics and Clinical Risk Management</i> , 2006 , 2, 365-75	2.9	31
116	Imaging in Ankylosing Spondylitis 2006 , 71-81		2
115	Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. <i>Journal of Rheumatology</i> , 2006 , 33, 681-9	4.1	45
114	Potential for altering rheumatoid arthritis outcome. <i>Rheumatic Disease Clinics of North America</i> , 2005 , 31, 763-72	2.4	12
113	Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. <i>Arthritis Research</i> , 2005 , 7, R80-92		58
112	Introduction. <i>Journal of Clinical Rheumatology</i> , 2005 , 11, S37-8	1.1	
111	How should we manage early rheumatoid arthritis? From imaging to intervention. <i>Current Opinion in Rheumatology</i> , 2005 , 17, 280-5	5.3	19
110	Are early arthritis clinics necessary?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005 , 19, 1-17	5.3	23

109	C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. <i>Arthritis and Rheumatism</i> , 2005 , 52, 42-8		88
108	Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2005 , 52, 27-35		451
107	Study of individual joint pathology in rheumatoid arthritis suggests a single pathology: comment on the editorial by Kirwan. <i>Arthritis and Rheumatism</i> , 2005 , 52, 672-3; author reply 673		
106	Recommendations for musculoskeletal ultrasonography by rheumatologists: setting global standards for best practice by expert consensus. <i>Arthritis and Rheumatism</i> , 2005 , 53, 83-92		73
105	Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2263-71		370
104	Co-stimulatory blockade as therapy for rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2005 , 7, 400-6	4.9	11
103	Adalimumab therapy: clinical findings and implications for integration into clinical guidelines for rheumatoid arthritis. <i>Drugs of Today</i> , 2005 , 41, 155-63		7
102	Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005 , 32, 590-601	4.1	59
101	Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005 , 32, 1620-31	4.1	20
100	Minimal disease activity for rheumatoid arthritis: a preliminary definition. <i>Journal of Rheumatology</i> , 2005 , 32, 2016-24	4.1	116
99	Magnetic resonance imaging in rheumatoid arthritis advances and research priorities. <i>Journal of Rheumatology</i> , 2005 , 32, 2462-4	4.1	15
98	The evidence for magnetic resonance imaging as an outcome measure in proof-of-concept rheumatoid arthritis studies. <i>Journal of Rheumatology</i> , 2005 , 32, 2465-9	4.1	16
97	Imaging in early arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2004 , 18, 927-43	5.3	19
96	Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade. <i>Arthritis and Rheumatism</i> , 2004 , 50, 725-8		63
95	The validity and predictive value of magnetic resonance imaging erosions in rheumatoid arthritis: comment on the article by Goldbach-Mansky et al. <i>Arthritis and Rheumatism</i> , 2004 , 50, 1009-11		3
94	Enumeration and phenotypic characterization of synovial fluid multipotential mesenchymal progenitor cells in inflammatory and degenerative arthritis. <i>Arthritis and Rheumatism</i> , 2004 , 50, 817-27		341
93	Regional variation and differential response to therapy for knee synovitis adjacent to the cartilage-pannus junction and suprapatellar pouch in inflammatory arthritis: implications for pathogenesis and treatment. <i>Arthritis and Rheumatism</i> , 2004 , 50, 2428-32		38
92	Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. <i>Arthritis and Rheumatism</i> , 2004 , 50, 3432-43		948

91	Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide. <i>Arthritis and Rheumatism</i> , 2004 , 50, 4072-3		16
90	Practice, training, and assessment among experts performing musculoskeletal ultrasonography: toward the development of an international consensus of educational standards for ultrasonography for rheumatologists. <i>Arthritis and Rheumatism</i> , 2004 , 51, 1018-22		35
89	Review of health economics modelling in rheumatoid arthritis. <i>Pharmacoeconomics</i> , 2004 , 22, 55-69	4.4	18
88	Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. <i>New England Journal of Medicine</i> , 2004 , 350, 2572-81	59.2	2009
87	Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: imaging technique. <i>Current Opinion in Rheumatology</i> , 2004 , 16, 435-42	5.3	10
86	Phenotypical, Morphological and Molecular Analysis of Fresh Human Bone Marrow Mesenchymal/Stromal Stem Cells (MSCs) Enriched by Four Different Methods.. <i>Blood</i> , 2004 , 104, 2337-2337		
85	Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. <i>Journal of Rheumatology</i> , 2004 , 31, 482-8	4.1	108
84	The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy. <i>Journal of rheumatology Supplement, The</i> , 2004 , 71, 13-20		16
83	Leflunomide: a manageable safety profile. <i>Journal of rheumatology Supplement, The</i> , 2004 , 71, 21-4		33
82	Lefunomide in combination therapy. <i>Journal of rheumatology Supplement, The</i> , 2004 , 71, 25-30		2
81	Imaging of the musculoskeletal system: magnetic resonance imaging, ultrasonography and computed tomography. <i>Best Practice and Research in Clinical Rheumatology</i> , 2003 , 17, 513-28	5.3	20
80	Pes planovalgus in RA: a descriptive and analytical study of foot function determined by gait analysis. <i>Musculoskeletal Care</i> , 2003 , 1, 21-33	1.6	41
79	Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003 , 48, 64-71		398
78	Role of metacarpophalangeal joint anatomic factors in the distribution of synovitis and bone erosion in early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003 , 48, 1214-22		201
77	Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol. <i>Arthritis and Rheumatism</i> , 2003 , 48, 3039-45		80
76	Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. <i>Arthritis and Rheumatism</i> , 2003 , 48, 3085-95		95
75	Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. <i>New England Journal of Medicine</i> , 2003 , 349, 1907-15	59.2	822
74	The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2003 , 12, 673-81	5.9	41

73	Angiopoietins, growth factors, and vascular morphology in early arthritis. <i>Journal of Rheumatology</i> , 2003 , 30, 260-8	4.1	136
72	Gout related upper limb cellulitis: an ultrasound study. <i>Journal of Rheumatology</i> , 2003 , 30, 417-9	4.1	8
71	Repair of erosions in rheumatoid arthritis does occur. Results from 2 studies by the OMERACT Subcommittee on Healing of Erosions. <i>Journal of Rheumatology</i> , 2003 , 30, 1102-7	4.1	53
70	OMERACT Rheumatoid Arthritis MRI Studies Module. <i>Journal of Rheumatology</i> , 2003 , 30, 1364-5	4.1	12
69	OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Exercise 3: an international multicenter reliability study using the RA-MRI Score. <i>Journal of Rheumatology</i> , 2003 , 30, 1366-75	4.1	85
68	OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Exercise 4: an international multicenter longitudinal study using the RA-MRI Score. <i>Journal of Rheumatology</i> , 2003 , 30, 1376-9	4.1	61
67	OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. <i>Journal of Rheumatology</i> , 2003 , 30, 1385-6	4.1	424
66	OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Summary of OMERACT 6 MR Imaging Module. <i>Journal of Rheumatology</i> , 2003 , 30, 1387-92	4.1	63
65	Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. <i>Journal of Rheumatology</i> , 2003 , 30, 2287-91	4.1	123
64	Role of adalimumab, a novel TNF antagonist in advancing rheumatoid arthritis control. <i>Drugs of Today</i> , 2003 , 39 Suppl B, 17-23	2.5	1
63	Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data. <i>Journal of Rheumatology</i> , 2003 , 30, 2572-9	4.1	30
62	Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2002 , 46, 366-72		198
61	High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: short-term efficacy correlates with reduction of macroscopic and histologic synovitis. <i>Arthritis and Rheumatism</i> , 2002 , 46, 837-9		37
60	The role of biomechanical factors and HLA-B27 in magnetic resonance imaging-determined bone changes in plantar fascia enthesopathy. <i>Arthritis and Rheumatism</i> , 2002 , 46, 489-93		145
59	Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1971-2; author reply 1973		20
58	Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1470-9		310
57	Magnetic resonance imaging as a predictor of progressive joint destruction in neuropathic joint disease. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2814-5		8
56	Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2034-8		236

55	The geometric architecture of the subtalar and midtarsal joints in rheumatoid arthritis based on magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2002 , 46, 3168-77		127
54	Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. <i>Arthritis and Rheumatism</i> , 2002 , 46, 3349-60		501
53	Advances in the understanding of enthesal inflammation. <i>Current Rheumatology Reports</i> , 2002 , 4, 500-64.9		52
52	Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. <i>Annals of the Rheumatic Diseases</i> , 2002 , 61, 290-7	2.4	255
51	Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. <i>Blood</i> , 2002 , 100, 4550-6	2.2	127
50	Magnetic resonance imaging: opportunities for rheumatoid arthritis disease assessment and monitoring long-term treatment outcomes. <i>Arthritis Research</i> , 2002 , 4 Suppl 2, S6-10		3
49	High dose immunosuppressive therapy and stem cell transplantation in autoimmune and inflammatory diseases. <i>International Immunopharmacology</i> , 2002 , 2, 399-414	5.8	5
48	Dose-effect relationships of nonsteroidal anti-inflammatory drugs: a literature review. <i>Clinical Therapeutics</i> , 2002 , 24, 1225-91	3.5	28
47	The concept of disease modification in spondyloarthropathy. <i>Journal of Rheumatology</i> , 2002 , 29, 1583-54.1		18
46	Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. <i>Journal of Rheumatology</i> , 2002 , 29, 2371-8	4.1	66
45	Evidence supporting the benefit of early intervention in rheumatoid arthritis. <i>Journal of rheumatology Supplement, The</i> , 2002 , 66, 3-8		41
44	Combination therapy in rheumatoid arthritis. <i>Seminars in Immunopathology</i> , 2001 , 23, 165-83		4
43	Autologous stem cell transplantation for rapidly progressive Jo-1-positive polymyositis with long-term follow-up. <i>British Journal of Haematology</i> , 2001 , 113, 840-1	4.5	24
42	Predictors of outcome in patients with oligoarthritis: results of a protocol of intraarticular corticosteroids to all clinically active joints. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1177-83		40
41	Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. <i>Arthritis and Rheumatism</i> , 2001 , 44, 2024-8		93
40	Efficacy of etanercept in the treatment of the enthesal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. <i>Arthritis and Rheumatism</i> , 2001 , 44, 2112-7		345
39	How do you diagnose rheumatoid arthritis early?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2001 , 15, 49-66	5.3	13
38	Imaging the joints in early rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2001 , 15, 91-104	5.3	21

37	Detection of Mycobacterium tuberculosis group organisms in human and mouse joint tissue by reverse transcriptase PCR: prevalence in diseased synovial tissue suggests lack of specific association with rheumatoid arthritis. <i>Infection and Immunity</i> , 2001 , 69, 1821-31	3.7	17
36	Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2001 , 2, 125-37	4	23
35	Infliximab: a new treatment for rheumatoid arthritis. <i>British Journal of Hospital Medicine</i> , 2001 , 62, 150-2		6
34	Rheumatoid arthritis synovial T cells regulate transcription of several genes associated with antigen-induced anergy. <i>Journal of Clinical Investigation</i> , 2001 , 107, 519-28	15.9	32
33	Leflunomide: a new DMARD for rheumatoid arthritis. <i>British Journal of Hospital Medicine</i> , 2000 , 61, 344-7		5
32	Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1888-98		148
31	The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. <i>Arthritis and Rheumatism</i> , 2000 , 43, 2762-70		470
30	Synovial biopsy in arthritis research: five years of concerted European collaboration. <i>Annals of the Rheumatic Diseases</i> , 2000 , 59, 506-11	2.4	29
29	Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2000 , 59, 504-5	2.4	41
28	Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. <i>New England Journal of Medicine</i> , 2000 , 343, 1594-602	59.2	2590
27	Autologous blood stem cell transplantation as therapy for autoimmune diseases. <i>Annals of Medicine</i> , 2000 , 32, 615-21	1.5	11
26	Established rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 1999 , 13, 561-75	5.3	39
25	Psoriatic arthritis: a unified concept twenty years on. <i>Arthritis and Rheumatism</i> , 1999 , 42, 1080-6		222
24	The relationship between synovitis and bone changes in early untreated rheumatoid arthritis: a controlled magnetic resonance imaging study. <i>Arthritis and Rheumatism</i> , 1999 , 42, 1706-11		310
23	Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. <i>Arthritis and Rheumatism</i> , 1999 , 42, 2184-8		128
22	Spondyloarthropathy. <i>Lancet, The</i> , 1999 , 353, 1526-1527	40	3
21	An anatomical explanation for good-prognosis rheumatoid arthritis. <i>Lancet, The</i> , 1999 , 353, 123-4	40	148
20	Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. <i>Lancet, The</i> , 1999 , 354, 2106-11	40	427

19	Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. <i>Lancet, The</i> , 1999 , 354, 1932-9	40	1960
18	Enthesitis in spondyloarthropathy. <i>Current Opinion in Rheumatology</i> , 1999 , 11, 244-50	53	108
17	Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. <i>Arthritis and Rheumatism</i> , 1998 , 41, 2196-204		799
16	Classification of inflammatory arthritis by enthesitis. <i>Lancet, The</i> , 1998 , 352, 1137-40	40	479
15	Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis. The impact on costs and outcomes in the UK. <i>Pharmacoeconomics</i> , 1998 , 14, 191-9	44	13
14	Rheumatoid arthritis: not yet curable with early intensive therapy. <i>Lancet, The</i> , 1997 , 350, 304-5	40	14
13	What is early rheumatoid arthritis?: definition and diagnosis. <i>Baillieres Clinical Rheumatology</i> , 1997 , 11, 13-26		25
12	A phase 1 study to address the safety and efficacy of granulocyte colony-stimulating factor for the mobilization of hematopoietic progenitor cells in active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1838-42		20
11	The clinical implications of inhibition of the inducible form of cyclo-oxygenase. <i>Drug Safety</i> , 1996 , 15, 249-60	51	27
10	Pirazolac. <i>BioDrugs</i> , 1996 , 6, 511-511		
9	DXA scanning. <i>Baillieres Clinical Rheumatology</i> , 1996 , 10, 679-98		4
8	Clinical use of cyclosporin in rheumatoid arthritis. <i>Drugs</i> , 1995 , 50 Suppl 1, 26-36	121	21
7	Innovative treatment approaches for rheumatoid arthritis. New cyclo-oxygenase and cytokine inhibitors. <i>Baillieres Clinical Rheumatology</i> , 1995 , 9, 731-58		11
6	A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. <i>European Journal of Immunology</i> , 1994 , 24, 191-5	61	198
5	Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. <i>Arthritis and Rheumatism</i> , 1994 , 37, 1166-70		166
4	8-Hydroxydeoxyguanosine. A marker of oxidative DNA damage in systemic lupus erythematosus. <i>FEBS Letters</i> , 1994 , 348, 131-8	38	111
3	Carbocysteine polymorphism and disease. <i>Lancet, The</i> , 1992 , 339, 616-7	40	7
2	Techetium 99m methylene diphosphonate bone scanning in osteoarthritic hands. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1991 , 18, 12-6		27

- ¹ Further evidence for the lack of association between acetylator phenotype and systemic lupus erythematosus. *Arthritis and Rheumatism*, **1987**, 30, 357-8

3